| Literature DB >> 31447460 |
Shizhou Wu1,2, Yunjie Liu3, Hui Zhang1, Lei Lei2.
Abstract
Staphylococcus aureus has the potential to opportunistically cause infectious diseases. The aim of this study was to determine the antimicrobial effects of novel graphene oxide (GO)-polyethylenimine (PEI)-based antisense yycG (ASyycG) on the inhibition of methicillin-resistant S. aureus (MRSA) biofilm formation. In current study, a novel GO-PEI-based recombinant ASyycG vector transformation strategy was developed to produce ASyycG. The mechanical features including zeta-potential and particle size distributions were evaluated by: GO; GO-PEI and GO-PEI-ASyycG. The recombinant ASyycG vector was transformed into MRSA cells, and the expression levels of the yycF/G and icaADB genes were determined and compared by quantitative real-time PCR (qPCR) assays. The recombinant ASyycG plasmids were subsequently modified with a gene encoding enhanced green fluorescent protein (ASyycG-eGFP) as a reporter gene, and the transformation efficiency was assessed by the fluorescence intensity. The biofilm biomass and bacterial viability of the MRSA strains were evaluated by crystal violet assay, colony-forming unit assays and confocal laser scanning microscopy. The results showed that the Z-average sizes of GO-PEI-ASyycG were much larger than those of GO or GO-PEI. The GO-PEI-based strategy significantly increased the efficiency of ASyycG transformation. The GO-PEI-ASyycG-transformed MRSA strain had the lowest expression levels of the biofilm formation-associated genes. Furthermore, GO-PEI-ASyycG suppressed biofilm aggregation and improved bactericidal effects on the MRSA after 24 hr of biofilm establishment. Our findings demonstrated that GO-PEI based antisense yycG RNA will be an effective method for management of MRSA infections.Entities:
Keywords: antisense RNA; biofilm; graphene oxide; methicillin-resistant Staphylococcus aureus
Mesh:
Substances:
Year: 2019 PMID: 31447460 PMCID: PMC6863726 DOI: 10.1292/jvms.19-0216
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Fig. 1.GO-PEI-ASyycG Increased ASyycG transformation and inhibited virulence gene expressions. (A) The transfection efficiency was determined by comparing the green fluorescent intensities by CLSM observation (n=10, *P<0.05; GO solution with concentration at 50 mg/ml determined by cell viability assay); (B) Quantitative RT-PCR analysis showed gene transcription in the MRSA strains using 16S rRNA as an internal control and calculated based on the MRSA expression, which was set as 1.0. Experiments were performed in triplicate and are presented as the mean ± standard deviation (n=10, *P<0.05; GO solution with concentration at 50 mg/ml determined by cell viability assay). MRSA (black) indicated the control samples of MRSA cells; ASyycG (green) indicated the samples treated with only recombinant pDL278 ASyycG plasmid; GO (blue) indicated the samples treated only with GO; GO+ASyycG (gray) indicated the samples treated with GO+PEI based ASyycG. The NO.4 clinical isolated strain was used in Fig. 1.
Fig. 2.GO-PEI-ASyycG suppressed bacterial growth and biofilm formation in MRSA biofilms. (A) Crystal violet staining for the MRSA strains; (B) Biomass was quantified by crystal violet staining; Optical densities at 600 nm were measured (n=10, *P<0.05); (C) Colony-forming units counting for the MRSA biofilms. MRSA (black) indicated the control samples of MRSA cells; ASyycG (green) indicated the samples treated with only recombinant pDL278 ASyycG plasmid; GO (blue) indicated the samples treated only with GO; GO+ASyycG (gray) indicated the samples treated with GO+PEI based ASyycG. The NO.4 clinical isolated strain was used in Fig. 2.
Fig. 3.GO-PEI-ASyycG suppressed the vital cells in MRSA biofilms. (A) Double labeling of the biofilms in the MRSA and ASyycG-, GO- and GO-PEI-ASyycG-treated strains (GO solution with concentration at 50 mg/ml determined by cell viability assay). Green, vital cells (SYTO 9); red, dead cells (PI); scale bars, 100 µm; (B) Volume ratio of the vital bacterial biomass in the biofilms (n=10, *P<0.05). The NO.4 clinical isolated strain was used in Fig. 3.